Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis

Brian I. Carr, William Irish, Michael P. Federle

Research output: Contribution to journalArticlepeer-review


Background/Aims: Chemoembolization in the presence of portal vein thrombosis (PVT) is thought to be hazardous and such patients are regarded as prognostically poor. Methodology: One hundred sixty two patients with biopsy-proven and unresectable HCC were treated with chemoembolization (TACE). We retrospectively analyzed these patients according to presence or absence of PVT. Results: We found the 2 groups were similar with respect to tumor and liver parameters. Survival was 22.3 months in responders and 6.6 months in non-responders, p≤0.0001. Patients with PVT who responded had a 24 mo median survival and without PVT who responded had a 30 month median survival. These 2 groups were thus similar, p=0.817. Patients who did not respond had a survival of only 5 and 7 months, for presence or absence of PVT, respectively. Responders had significantly lower blood AFP and GGTP levels, lower DCP levels and better liver function. Conclusions: In this series, response was a major determinant of survival, regardless of the presence or absence of PVT. Thus, branch PVT was not a contraindication to chemoembolization.

Original languageEnglish
Pages (from-to)1375-1381
Number of pages7
Issue number104
Publication statusPublished - Nov 2010


  • Chemoembolization
  • PVT
  • Responses
  • Survival
  • TACE

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis'. Together they form a unique fingerprint.

Cite this